Document Detail


Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.
MedLine Citation:
PMID:  10961959     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: NOGA left ventricular (LV) electromechanical mapping (EMM) can be used to distinguish among infarcted, ischemic, and normal myocardium. We investigated the use of percutaneous LV EMM to assess the efficacy of myocardial gene transfer (GTx) of naked plasmid DNA encoding for vascular endothelial growth factor (phVEGF(165)), administered during surgery by direct myocardial injection in patients with chronic myocardial ischemia. METHODS AND RESULTS: A total of 13 consecutive patients (8 men, mean age 60.1+/-2. 3 years) with chronic stable angina due to angiographically documented coronary artery disease, all of whom had failed conventional therapy (drugs, PTCA, and/or CABG), were treated with direct myocardial injection of phVEGF(165) via a minithoracotomy. Foci of ischemic myocardium were identified on LV EMM by preserved viability associated with an impairment in linear local shortening. Myocardial viability, defined by mean unipolar and bipolar voltage recordings >/=5 and >/=2 mV, respectively, did not change significantly after GTx. Analysis of linear local shortening in areas of myocardial ischemia, however, disclosed significant improvement after (15.26+/-0.98%) versus before (9.94+/-1.53%, P:=0. 004) phVEGF(165) GTx. The area of ischemic myocardium was consequently reduced from 6.45+/-1.37 cm(2) before GTx to 0.95+/-0. 41 cm(2) after GTx (P:=0.001). These findings corresponded to improved perfusion scores calculated from single-photon emission CT-sestamibi myocardial perfusion scans recorded at rest (7.4+/-2.1 before GTx versus 4.5+/-1.4 after GTx, P:=0.009) and after pharmacological stress (12.8+/-2.7 before GTx versus 8.5+/-1.7 after GTx, P:=0.047). CONCLUSIONS: The results of EMM constitute objective evidence that phVEGF(165) GTx augments perfusion of ischemic myocardium. These findings, together with reduction in the size of the defects documented at rest by serial single-photon emission CT-sestamibi imaging, suggest that phVEGF(165) GTx may successfully rescue foci of hibernating myocardium.
Authors:
P R Vale; D W Losordo; C E Milliken; M Maysky; D D Esakof; J F Symes; J M Isner
Related Documents :
1476269 - Diagnosis of coronary artery disease with tc 99m-methoxy isobutyl isonitrile and transe...
25394989 - Renal denervation in the treatment of resistant arterial hypertension.
8790039 - Assessment of myocardial viability with 99mtc sestamibi in patients undergoing cardiac ...
9381999 - Incremental value of rubidium-82 positron emission tomography for prognostic assessment...
15984909 - Effects of trimetazidine on myocardial perfusion and the contractile response of chroni...
25377279 - Cerebral amyloid angiopathy related hemorrhage after stroke thrombolysis: case report a...
12653689 - Natriuretic peptides maintain sodium homoeostasis during chronic volume loading post-my...
6201299 - Postextrasystolic alterations in refractoriness of the his-purkinje system and ventricu...
11174899 - Cardiac pacing in infants and children.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  102     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-09-14     Completed Date:  2000-09-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  965-74     Citation Subset:  IM    
Affiliation:
Division of Cardiology and Vascular Medicine, St. Elizabeth's Medical Center, Boston, MA 02135, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inducing Agents / therapeutic use
Coronary Circulation / drug effects
Electrocardiography / methods
Endothelial Growth Factors / genetics*,  therapeutic use
Gene Therapy / methods*
Gene Transfer Techniques
Heart / physiopathology,  radionuclide imaging
Humans
Lymphokines / genetics*,  therapeutic use
Male
Microinjections
Middle Aged
Myocardial Ischemia / physiopathology,  radionuclide imaging,  therapy*
Neovascularization, Physiologic*
Plasmids / therapeutic use
Thoracotomy
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Ventricular Function, Left
Chemical
Reg. No./Substance:
0/Angiogenesis Inducing Agents; 0/Endothelial Growth Factors; 0/Lymphokines; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors
Comments/Corrections
Comment In:
Circulation. 2000 Aug 29;102(9):940-2   [PMID:  10961953 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo w...
Next Document:  Physical activity and coronary heart disease in men: The Harvard Alumni Health Study.